| 1 |
Wladis EJ, Wrzesinski SH, Rothschild MI, Adam AP. Emerging therapeutic options for periorbital and orbital cutaneous basal and squamous cell carcinomas. Orbit 2023;42:117-23. [PMID: 36214105 DOI: 10.1080/01676830.2022.2130363] [Reference Citation Analysis]
|
| 2 |
Iliadi C, Verset L, Bouchart C, Martinive P, Van Gestel D, Krayem M. The current understanding of the immune landscape relative to radiotherapy across tumor types. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1148692] [Reference Citation Analysis]
|
| 3 |
Muin D, Laukhtina E, Hacker M, Shariat SF. PET in bladder cancer imaging. Curr Opin Urol 2023. [PMID: 36876730 DOI: 10.1097/MOU.0000000000001090] [Reference Citation Analysis]
|
| 4 |
Li Z, Kim H, Kim J, Park JH. EP400NL is involved in PD-L1 gene activation by forming a transcriptional coactivator complex. Biochim Biophys Acta Gene Regul Mech 2023;1866:194889. [PMID: 36328277 DOI: 10.1016/j.bbagrm.2022.194889] [Reference Citation Analysis]
|
| 5 |
Metaxas GI, Tsiambas E, Marinopoulos S, Adamopoulou M, Spyropoulou D, Falidas E, Davris D, Manaios L, Fotiades P, Mastronikoli S, Peschos D, Dimitrakakis C. DNA Mismatch Repair System Imbalances in Breast Adenocarcinoma. Cancer Diagn Progn 2023;3:169-74. [PMID: 36875308 DOI: 10.21873/cdp.10197] [Reference Citation Analysis]
|
| 6 |
Patruni S, Fayyaz F, Bien J, Phillip T, King DA. Immunotherapy in the Management of Esophagogastric Cancer: A Practical Review. JCO Oncol Pract 2023;19:107-15. [PMID: 36409967 DOI: 10.1200/OP.22.00226] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 7 |
Zhand S, Zhu Y, Nazari H, Sadraeian M, Warkiani ME, Jin D. Thiolate DNAzymes on Gold Nanoparticles for Isothermal Amplification and Detection of Mesothelioma-derived Exosomal PD-L1 mRNA. Anal Chem 2023;95:3228-37. [PMID: 36624066 DOI: 10.1021/acs.analchem.2c04046] [Reference Citation Analysis]
|
| 8 |
Zhang Z, Xiong Q, Xu Y, Cai X, Zhang L, Zhu Q. The PD-L1 Expression and Tumor-Infiltrating Immune Cells Predict an Unfavorable Prognosis in Pancreatic Ductal Adenocarcinoma and Adenosquamous Carcinoma. J Clin Med 2023;12. [PMID: 36835933 DOI: 10.3390/jcm12041398] [Reference Citation Analysis]
|
| 9 |
Jung M, Rose M, Knuechel R, Loeffler C, Muti H, Kather JN, Gaisa NT; German Study Group of Bladder Cancer (DFBK e.V.). Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer. BMC Cancer 2023;23:113. [PMID: 36726072 DOI: 10.1186/s12885-023-10576-0] [Reference Citation Analysis]
|
| 10 |
Song S, Zhang Y, Duan X, Liu C, Du Y, Wang X, Luo Y, Cui Y. HIF-1α/IL-8 axis in hypoxic macrophages promotes esophageal cancer progression by enhancing PD-L1 expression. Cancer Gene Ther 2023;30:358-67. [PMID: 36357565 DOI: 10.1038/s41417-022-00551-5] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 11 |
Zhang K, Yin W, Ma L, Liu Z, Li Q. HSPB8 facilitates prostate cancer progression via activating the JAK/STAT3 signaling pathway. Biochem Cell Biol 2023;101:1-11. [PMID: 36318825 DOI: 10.1139/bcb-2022-0205] [Reference Citation Analysis]
|
| 12 |
Kovalenko LP, Korzhova KV, Nikitin SV, Ivanova EA, Zhurikov RV. [Correction of serum prooncogenic cytokines and metastases by 5-hydroxypyrimidine derivatives and doxorubicin after removal of a primary tumor node in mice with the Lewis lung epidermoid carcinoma]. Biomed Khim 2023;69:39-45. [PMID: 36857425 DOI: 10.18097/PBMC20236901039] [Reference Citation Analysis]
|
| 13 |
Wei P, Jia H, Li R, Zhang C, Guo S, Wei S, Sun K, Cheng S, Cui T, Huang J, Guo S, Guo J, Yang Z, Zhong J, Lu C, Feng Z, Zhao T. Fluvoxamine prompts the antitumor immune effect via inhibiting the PD-L1 expression on mice-burdened colon tumor. Cell Biol Int 2023;47:439-50. [PMID: 36259746 DOI: 10.1002/cbin.11936] [Reference Citation Analysis]
|
| 14 |
Yan T, Yu L, Shangguan D, Li W, Liu N, Chen Y, Fu Y, Tang J, Liao D. Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors. Int Immunopharmacol 2023;115:109638. [PMID: 36587500 DOI: 10.1016/j.intimp.2022.109638] [Reference Citation Analysis]
|
| 15 |
Moon Y, Jeon SI, Shim MK, Kim K. Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy. Pharmaceutics 2023;15. [PMID: 36839734 DOI: 10.3390/pharmaceutics15020411] [Reference Citation Analysis]
|
| 16 |
Dimitrova YN, Gutierrez JA, Huard K. It's ok to be outnumbered - sub-stoichiometric modulation of homomeric protein complexes. RSC Med Chem 2023;14:22-46. [PMID: 36760737 DOI: 10.1039/d2md00212d] [Reference Citation Analysis]
|
| 17 |
Zhou Y, Li G, Wang J, Liu M, Wang Z, Song Y, Zhang X, Wang X. PD-L1: expression regulation. Blood Science 2023;Publish Ahead of Print. [DOI: 10.1097/bs9.0000000000000149] [Reference Citation Analysis]
|
| 18 |
Ngan Ngo TK, Kuo CH, Tu TY. Recent advances in microfluidic-based cancer immunotherapy-on-a-chip strategies. Biomicrofluidics 2023;17:011501. [PMID: 36647540 DOI: 10.1063/5.0108792] [Reference Citation Analysis]
|
| 19 |
Ledderose S, Schulz H, Paul T, Ledderose C, Ledderose GJ. Characterization of the tumor-infiltrating lymphocyte landscape in sinonasal mucosal melanoma. Pathol Res Pract 2023;241:154289. [PMID: 36584498 DOI: 10.1016/j.prp.2022.154289] [Reference Citation Analysis]
|
| 20 |
Shao K, Shen H, Chen X, Shao Z, Liu Y, Wang Y, Chen H, Wu X. Copper transporter gene ATP7A: A predictive biomarker for immunotherapy and targeted therapy in hepatocellular carcinoma. Int Immunopharmacol 2023;114:109518. [PMID: 36502594 DOI: 10.1016/j.intimp.2022.109518] [Reference Citation Analysis]
|
| 21 |
Jiang Y, Yu L, Hu Q, Kang Y, You J, Huang C, Xu X, Chen L. Cancer/testis antigen HEMGN correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma. Mol Immunol 2023;153:226-37. [PMID: 36563642 DOI: 10.1016/j.molimm.2022.12.008] [Reference Citation Analysis]
|
| 22 |
Walker RR, Rentia Z, Chiappinelli KB. Epigenetically programmed resistance to chemo- and immuno-therapies. Advances in Cancer Research 2023. [DOI: 10.1016/bs.acr.2022.12.001] [Reference Citation Analysis]
|
| 23 |
Kuol N, Davidson M, Karakkat J, Filippone RT, Veale M, Luwor R, Fraser S, Apostolopoulos V, Nurgali K. Blocking Muscarinic Receptor 3 Attenuates Tumor Growth and Decreases Immunosuppressive and Cholinergic Markers in an Orthotopic Mouse Model of Colorectal Cancer. Int J Mol Sci 2022;24. [PMID: 36614038 DOI: 10.3390/ijms24010596] [Reference Citation Analysis]
|
| 24 |
Wang Y, Wang N, Huang Z, Lu Z, Guo T, Meng G. The heterogeneity of PD-L1 protein in gastric cancer: expression and distribution characteristics. Heliyon 2022;8:e12456. [PMID: 36593830 DOI: 10.1016/j.heliyon.2022.e12456] [Reference Citation Analysis]
|
| 25 |
Ren J, He Q, Yin H, Zheng L, Li L, Wu X. Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and programmed death ligand 1 (PD-L1) expression in gastric cancer: a systematic review and meta-analysis. Clin Transl Oncol 2022. [DOI: 10.1007/s12094-022-03040-1] [Reference Citation Analysis]
|
| 26 |
Tap WD, Healey JH. Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor. Tumour Biol 2022;44:239-48. [PMID: 36502356 DOI: 10.3233/TUB-220005] [Reference Citation Analysis]
|
| 27 |
Pfister DG, Haddad RI, Worden FP, Weiss J, Mehra R, Chow LQM, Liu SV, Kang H, Saba NF, Wirth LJ, Sukari A, Massarelli E, Ayers M, Albright A, Webber AL, Mogg R, Lunceford J, Huang L, Cristescu R, Cheng J, Seiwert TY, Bauml JM. Biomarkers predictive of response to pembrolizumab in head and neck cancer. Cancer Medicine 2022. [DOI: 10.1002/cam4.5434] [Reference Citation Analysis]
|
| 28 |
Jovanović L, Ćirković A, Jović M, Janković R. PD-L1 Expression in High-Grade Serous and Clear Cell Ovarian Cancer. Indian J Gynecol Oncolog 2022;20:47. [DOI: 10.1007/s40944-022-00658-5] [Reference Citation Analysis]
|
| 29 |
Hou W, Yi C, Zhu H. Predictive biomarkers of colon cancer immunotherapy: Present and future. Front Immunol 2022;13:1032314. [PMID: 36483562 DOI: 10.3389/fimmu.2022.1032314] [Reference Citation Analysis]
|
| 30 |
Mulgaonkar A, Elias R, Woolford L, Guan B, Nham K, Kapur P, Christie A, Tcheuyap VT, Singla N, Bowman IA, Stevens C, Hao G, Brugarolas J, Sun X. ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma. Clin Cancer Res 2022;28:4907-16. [PMID: 36074149 DOI: 10.1158/1078-0432.CCR-22-1547] [Reference Citation Analysis]
|
| 31 |
Hadrava vanova K, Uher O, Meuter L, Ghosal S, Talvacchio S, Patel M, Neuzil J, Pacak K. PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1045517] [Reference Citation Analysis]
|
| 32 |
Reis IB, Tibo LHS, de Souza BR, Durán N, Fávaro WJ. OncoTherad® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer. J Cancer Res Clin Oncol 2022. [DOI: 10.1007/s00432-022-04449-5] [Reference Citation Analysis]
|
| 33 |
Liu J, Yu Z, Xu R, Zhang Z, Hong X, Wang S, Chen G, Tian Z. The second near-infrared window quantum dot-based fluorescence anisotropy probes for separation-free, sensitive and rapid detection of small extracellular vesicle PD-L1 in plasma samples. Sensors and Actuators B: Chemical 2022. [DOI: 10.1016/j.snb.2022.132962] [Reference Citation Analysis]
|
| 34 |
Hudson K, Cross N, Jordan-mahy N, Leyland R. Programmed death-ligand 1 expression in human cancer three-dimensional cell culture models.. [DOI: 10.1101/2022.10.31.514495] [Reference Citation Analysis]
|
| 35 |
Parosanu A, Stanciu IM, Pirlog C, Orlov Slavu C, Cotan H, Iaciu C, Popa AM, Olaru M, Moldoveanu O, Catalin B, Nitipir C. Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy. Cureus 2022. [DOI: 10.7759/cureus.30821] [Reference Citation Analysis]
|
| 36 |
Iscaro A, H.n. Howard F, Yang Z, Jenkins F, Muthana M. Perspective Chapter: Liposome Mediated Delivery of Immunotherapeutics for Cancer. Liposomes - Recent Advances, New Perspectives and Applications [Working Title] 2022. [DOI: 10.5772/intechopen.108282] [Reference Citation Analysis]
|
| 37 |
Xie Y, Kong W, Zhao X, Zhang H, Luo D, Chen S. Immune checkpoint inhibitors in cervical cancer: Current status and research progress. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.984896] [Reference Citation Analysis]
|
| 38 |
Lopez DC, Robbins YL, Kowalczyk JT, Lassoued W, Gulley JL, Miettinen MM, Gallia GL, Allen CT, Hodge JW, London NR. Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies. Front Oncol 2022;12:1012058. [DOI: 10.3389/fonc.2022.1012058] [Reference Citation Analysis]
|
| 39 |
Grottoli M, Carrega P, Zullo L, Dellepiane C, Rossi G, Parisi F, Barletta G, Zinoli L, Coco S, Alama A, Marconi S, Parodi M, Orecchia P, Bassi S, Vitale M, Mingari MC, Pfeffer U, Genova C, Pietra G. Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy. Cancers (Basel) 2022;14:5046. [PMID: 36291830 DOI: 10.3390/cancers14205046] [Reference Citation Analysis]
|
| 40 |
Dong M, Qian M, Ruan Z. CUL3/SPOP complex prevents immune escape and enhances chemotherapy sensitivity of ovarian cancer cells through degradation of PD-L1 protein. J Immunother Cancer 2022;10:e005270. [PMID: 36198437 DOI: 10.1136/jitc-2022-005270] [Reference Citation Analysis]
|
| 41 |
Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L, Wang S. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol 2022;13:964442. [DOI: 10.3389/fimmu.2022.964442] [Reference Citation Analysis]
|
| 42 |
Chen R, Niu L, Wu L, He Y, Liu G, Hong K. Identification of an endoplasmic reticulum stress-associated gene signature to predict the immune status and prognosis of cutaneous melanoma. Medicine (Baltimore) 2022;101:e30280. [PMID: 36086718 DOI: 10.1097/MD.0000000000030280] [Reference Citation Analysis]
|
| 43 |
Zhang Z, Jin W, Xu K, Zheng X, Zhou Y, Luo M, Yan C, Zheng X, Jin E. Blood exosome PD-L1 is associated with PD-L1 expression measured by immunohistochemistry, and lymph node metastasis in lung cancer. Tissue and Cell 2022. [DOI: 10.1016/j.tice.2022.101941] [Reference Citation Analysis]
|
| 44 |
Ge S, Jia T, Li J, Zhang B, Sang S, Deng S. Molecular imaging of immune checkpoints in oncology: Current and future applications. Cancer Lett 2022;:215896. [PMID: 36041658 DOI: 10.1016/j.canlet.2022.215896] [Reference Citation Analysis]
|
| 45 |
Zanello A, Bortolotti M, Maiello S, Bolognesi A, Polito L. Anti-PD-L1 immunoconjugates for cancer therapy: Are available antibodies good carriers for toxic payload delivering? Front Pharmacol 2022;13:972046. [DOI: 10.3389/fphar.2022.972046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 46 |
Mao J, Yang C, Xin S, Cui K, Liu Z, Wang T, Hu Z, Wang S, Liu J, Song X, Song W. Case report: Bladder preserving after maximal transurethral resection of the bladder tumor combined with chemotherapy and immunotherapy in recurrent muscle-invasive bladder cancer patients: A report of two cases. Front Med 2022;9. [DOI: 10.3389/fmed.2022.949567] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 47 |
Deng R, Zheng H, Cai H, Li M, Shi Y, Ding S. Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses. Front Immunol 2022;13:923477. [DOI: 10.3389/fimmu.2022.923477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 48 |
Nteli P, Bajwa DE, Politakis D, Michalopoulos C, Kefala-Narin A, Efstathopoulos EP, Gazouli M. Nanomedicine approaches for treatment of hematologic and oncologic malignancies. World J Clin Oncol 2022; 13(7): 553-566 [DOI: 10.5306/wjco.v13.i7.553] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 49 |
Li B, Wang B. USP7 Enables Immune Escape of Glioma Cells by Regulating PD-L1 Expression. Immunological Investigations. [DOI: 10.1080/08820139.2022.2083972] [Reference Citation Analysis]
|
| 50 |
Yu P, He W, Zhang Y, Hu C, Wu Y, Wang Y, Bao Z, Xia Y, Zhang R, Cao M, Yuan L, Cheng X, Xu Z, Cui Q. SFRP4 Is a Potential Biomarker for the Prognosis and Immunotherapy for Gastric Cancer. Journal of Oncology 2022;2022:1-15. [DOI: 10.1155/2022/8829649] [Reference Citation Analysis]
|
| 51 |
Bojko M, Węgrzyn K, Sikorska E, Kocikowski M, Parys M, Battin C, Steinberger P, Kogut MM, Winnicki M, Sieradzan AK, Spodzieja M, Rodziewicz-motowidło S. Design, synthesis and biological evaluation of PD-1 derived peptides as inhibitors of PD-1/PD-L1 complex formation for cancer therapy. Bioorganic Chemistry 2022. [DOI: 10.1016/j.bioorg.2022.106047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 52 |
Li X, Zhou X, Liu J, Zhang J, Feng Y, Wang F, He Y, Wan A, Filipczak N, Yalamarty SSK, Jin Y, Torchilin VP. Liposomal Co-delivery of PD-L1 siRNA/Anemoside B4 for Enhanced Combinational Immunotherapeutic Effect. ACS Appl Mater Interfaces 2022. [PMID: 35726706 DOI: 10.1021/acsami.2c01123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 53 |
Chen C, Luo J, Wang X. Identification of prostate cancer subtypes based on immune signature scores in bulk and single-cell transcriptomes. Med Oncol 2022;39:123. [PMID: 35716212 DOI: 10.1007/s12032-022-01719-7] [Reference Citation Analysis]
|
| 54 |
Kuryk L, Rodella G, Staniszewska M, Pancer KW, Wieczorek M, Salmaso S, Caliceti P, Garofalo M. Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects. Front Oncol 2022;12:916839. [DOI: 10.3389/fonc.2022.916839] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 55 |
Li X, Ji Y, Chen M, Zhang S, Wang Z, Su D, Luo N. A Dual-Mode Imaging Nanoparticle Probe Targeting PD-L1 for Triple-Negative Breast Cancer. Contrast Media Mol Imaging 2022;2022:2431026. [PMID: 35694705 DOI: 10.1155/2022/2431026] [Reference Citation Analysis]
|
| 56 |
Malicki S, Pucelik B, Żyła E, Benedyk-machaczka M, Gałan W, Golda A, Sochaj-gregorczyk A, Kamińska M, Encarnação JC, Chruścicka B, Marti H, Chen TJ, Magiera-mularz K, Zięba B, Holak TA, Dąbrowski JM, Czarna A, Kozieł J, Mydel P, Dubin G. Imaging of Clear Cell Renal Carcinoma with Immune Checkpoint Targeting Aptamer-Based Probe. Pharmaceuticals 2022;15:697. [DOI: 10.3390/ph15060697] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 57 |
Urban VA, Nazarenko PS, Perepechko SA, Veresov VG. Using PD-L1 full-length structure, enhanced induced fit docking and molecular dynamics simulations for structural insights into inhibition of PD-1/PD-L1 interaction by small-molecule ligands. Molecular Simulation. [DOI: 10.1080/08927022.2022.2080824] [Reference Citation Analysis]
|
| 58 |
Gao LM, Zhang YH, Shi X, Liu Y, Wang J, Zhang WY, Liu WP. The Role of PD-L1 Expression in Prediction and Stratification of Recurrent or Refractory Extranodal Natural Killer/T-Cell Lymphoma. Front Oncol 2022;12:821918. [PMID: 35619907 DOI: 10.3389/fonc.2022.821918] [Reference Citation Analysis]
|
| 59 |
Liu X, Ma C, Liu H, Sun Z, Luo J. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer. J Cancer Res Clin Oncol 2022. [PMID: 35596010 DOI: 10.1007/s00432-022-04032-y] [Reference Citation Analysis]
|
| 60 |
Hamed MM, Gouida MS, Abd El-aziz SR, El-sokkary AM. Evaluation PD-L1, CD8 and CD20 as early predictor and tracking markers for breast cancer (BC) in Egypt. Heliyon 2022;8:e09474. [DOI: 10.1016/j.heliyon.2022.e09474] [Reference Citation Analysis]
|
| 61 |
Tan Q, Yin S, Zhou D, Chi Y, Man X, Li H. Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer. Front Oncol 2022;12:779786. [DOI: 10.3389/fonc.2022.779786] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 62 |
Song Q, Yang B, Sheng W, Zhou Z, Zhang T, Qin B, Ji L, Li P, Wang D, Zhang X, Sun S, Zhang G, Zhao X, Gan Q, Xiong Q, Guan Y, Xia X, Yi X, Chen X, Guo W, Jiao S. Safety and efficacy of mutant neoantigen-specific T-cell treatment combined anti-PD-1 therapy in stage IV solid tumors. Immunotherapy 2022. [PMID: 35321561 DOI: 10.2217/imt-2021-0105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 63 |
Peña-cardelles JF, Pozo-kreilinger JJ, Roncador G, Esteban-hernández J, Moro-rodríguez JE, Sastre-perona A, Castelo-fernández B, Cebrián-carretero JL. Prognosis Value of Immunoregulatory Molecules in Oral Cancer Microenvironment: An Immunohistochemical Study. Biomedicines 2022;10:710. [DOI: 10.3390/biomedicines10030710] [Reference Citation Analysis]
|
| 64 |
Chen Q, Hu J, Hu X, Koh K, Chen H. Current methods and emerging approaches for detection of programmed death ligand 1. Biosens Bioelectron 2022;208:114179. [PMID: 35364526 DOI: 10.1016/j.bios.2022.114179] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 65 |
Jiang G, Hong J, Shao F, Wen Q, Cheng F, Yu T, Zhu J. Evolution of Immunotherapy for Ovarian Cancer from a Bird's-Eye Perspective: A Text-Mining Analysis of Publication Trends and Topics. Front Oncol 2022;12:795129. [PMID: 35280816 DOI: 10.3389/fonc.2022.795129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 66 |
Yaseen MM, Abuharfeil NM, Darmani H. The clinical and prognostic significance of CMTM6/PD-L1 in oncology. Clin Transl Oncol 2022. [PMID: 35278198 DOI: 10.1007/s12094-022-02811-0] [Reference Citation Analysis]
|
| 67 |
Yang M, Jiang C, Li L, Xing H, Hong L, Wang F. Expression of CD47 in Endometrial Cancer and Its Clinicopathological Significance. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/7188972] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 68 |
Cammarota A, Zanuso V, D'Alessio A, Pressiani T, Bozzarelli S, Personeni N, Rimassa L. The dual checkpoint blockade in unresectable hepatocellular carcinoma: Opportunities emerging in clinical trials. Expert Opin Investig Drugs 2022. [PMID: 35152830 DOI: 10.1080/13543784.2022.2042253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 69 |
El Ahanidi H, El Azzouzi M, Hafidi Alaoui C, Tetou M, Bensaid M, Chaoui I, Benbacer L, Hassan I, Oukabli M, Michaud K, Ameur A, Al Bouzidi A, El Mzibri M, Jandus C, Attaleb M. Immune Checkpoint and Telomerase Crosstalk Is Mediated by miRNA-138 in Bladder Cancer. Front Oncol 2022;11:795242. [DOI: 10.3389/fonc.2021.795242] [Reference Citation Analysis]
|
| 70 |
Yarmishyn AA, Ishola AA, Chen CY, Verusingam ND, Rengganaten V, Mustapha HA, Chuang HK, Teng YC, Phung VL, Hsu PK, Lin WC, Ma HI, Chiou SH, Wang ML. Circular RNAs Modulate Cancer Hallmark and Molecular Pathways to Support Cancer Progression and Metastasis. Cancers (Basel) 2022;14:862. [PMID: 35205610 DOI: 10.3390/cancers14040862] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 71 |
Sabbatino F, Liguori L, Pepe S, Ferrone S. Immune checkpoint inhibitors for the treatment of melanoma. Expert Opin Biol Ther 2022. [PMID: 35130816 DOI: 10.1080/14712598.2022.2038132] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 72 |
Robert C, Lewis K, Gutzmer R, Stroyakovskiy D, Gogas H, Protsenko S, Pereira R, Eigentler T, Rutkowski P, Demidov L, Caro I, Forbes H, Shah K, Yan Y, Li H, Mcarthur G, Ascierto P. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma. Annals of Oncology 2022. [DOI: 10.1016/j.annonc.2022.01.076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 73 |
Taber A, Prip F, Lamy P, Agerbæk M, Jensen JB, Steiniche T, Dyrskjøt L. Immune Contexture and Differentiation Features Predict Outcome in Bladder Cancer. European Urology Oncology 2022. [DOI: 10.1016/j.euo.2022.01.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 74 |
Saleh RR, Scott JL, Meti N, Perlon D, Fazelzad R, Ocana A, Amir E. Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis. Mol Diagn Ther 2022. [PMID: 35106739 DOI: 10.1007/s40291-022-00576-4] [Reference Citation Analysis]
|
| 75 |
Barakat S, Berksoz M, Zahedimaram P, Piepoli S, Erman B. Nanobodies as molecular imaging probes. Free Radical Biology and Medicine 2022. [DOI: 10.1016/j.freeradbiomed.2022.02.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 76 |
Yang A, Wu M, Ni M, Zhang L, Li M, Wei P, Yang Y, Xiao W, An X. A risk scoring system based on tumor microenvironment cells to predict prognosis and immune activity in triple-negative breast cancer. Breast Cancer. [DOI: 10.1007/s12282-021-01326-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 77 |
Fu R, Luo X, Ding Y, Guo S. Prognostic Potential of METTL7B in Glioma. Neuroimmunomodulation 2022;:1-16. [PMID: 35034026 DOI: 10.1159/000519778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 78 |
Wu C, Chow M, Temby M, McCalmont TH, Daud A. Response to PD-1 Immunotherapy in Metastatic Spiradenocarcinoma. JCO Precis Oncol 2021;5:340-3. [PMID: 34994598 DOI: 10.1200/PO.20.00285] [Reference Citation Analysis]
|
| 79 |
Núñez Abad M, Calabuig-Fariñas S, Lobo de Mena M, Torres-Martínez S, García González C, García García JÁ, Iranzo González-Cruz V, Camps Herrero C. Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer. Cancers (Basel) 2022;14:307. [PMID: 35053471 DOI: 10.3390/cancers14020307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 80 |
Wu Y, Dutta P, Clayton S, McCloud A, Vadgama JV. Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women. J Clin Med 2022;11:283. [PMID: 35053979 DOI: 10.3390/jcm11020283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 81 |
Altan M, Zhong L, Shannon VR, Sheshadri A. Pulmonary Toxicities of Immunotherapy. Adv Exp Med Biol 2021;1342:357-75. [PMID: 34972974 DOI: 10.1007/978-3-030-79308-1_14] [Reference Citation Analysis]
|
| 82 |
Singh M, Dahal A, de Sauvage M, Larson J, Brastianos PK. Biology and pathophysiology of central nervous system metastases. Neurological Complications of Systemic Cancer and Antineoplastic Therapy 2022. [DOI: 10.1016/b978-0-12-821976-8.00031-1] [Reference Citation Analysis]
|
| 83 |
Ahmed N, Benny K, Siraj S, Ali H, Basha R. Precision medicine approaches for treating hepatocellular carcinoma. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3 2022. [DOI: 10.1016/b978-0-323-99283-1.00002-1] [Reference Citation Analysis]
|
| 84 |
Zhou Y, Fang Y, Zhou J, Liu Y, Wu S, Xu B. NPM1 is a Novel Therapeutic Target and Prognostic Biomarker for Ewing Sarcoma. Front Genet 2021;12:771253. [PMID: 34899858 DOI: 10.3389/fgene.2021.771253] [Reference Citation Analysis]
|
| 85 |
Pansy K, Uhl B, Krstic J, Szmyra M, Fechter K, Santiso A, Thüminger L, Greinix H, Kargl J, Prochazka K, Feichtinger J, Deutsch AJ. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. Int J Mol Sci 2021;22:13311. [PMID: 34948104 DOI: 10.3390/ijms222413311] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 86 |
Wen F, Ruan S, Huang W, Chen X, Wang Y, Gu S, Liu J, Liu S, Shu P. Prognostic Value of Tumor Mutational Burden Related to Immune Infiltration in Cervical Squamous Cell Carcinoma. Front Med (Lausanne) 2021;8:755657. [PMID: 34859010 DOI: 10.3389/fmed.2021.755657] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 87 |
Kubli SP, Berger T, Araujo DV, Siu LL, Mak TW. Beyond immune checkpoint blockade: emerging immunological strategies. Nat Rev Drug Discov 2021;20:899-919. [PMID: 33686237 DOI: 10.1038/s41573-021-00155-y] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 46.0] [Reference Citation Analysis]
|
| 88 |
An R, Zhao F, Wang L, Shan J, Wang X. Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review. BMJ Open 2021;11:e047663. [DOI: 10.1136/bmjopen-2020-047663] [Reference Citation Analysis]
|
| 89 |
Wang CC, Huang KT, Chang HC, Tseng CC, Lai CH, Lan J, Liu TT, Huang CC, Lin MC. Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue. Thorac Cancer 2021. [PMID: 34841687 DOI: 10.1111/1759-7714.14216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 90 |
Du F, Liu Y. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer. J Clin Lab Anal 2021;:e24141. [PMID: 34817097 DOI: 10.1002/jcla.24141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 91 |
Nakamura M, Morita A. Immune activity in Merkel cell carcinoma. J Dermatol 2021. [PMID: 34766373 DOI: 10.1111/1346-8138.16232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 92 |
Jian D, Qian C, Wang D, Ma Q, Wang L, Li C, Xu M, Dai N, Chen Q, He J, Zhang H, Yuan M, Chen R, Chao R, Feng Y. Conversion therapy with tislelizumab for high microsatellite instability, unresectable stage III gastric cancer: a case report. Ann Transl Med 2021;9:1489. [PMID: 34734041 DOI: 10.21037/atm-21-4295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 93 |
Li C, Yang F, Wang R, Li W, Maskey N, Zhang W, Guo Y, Liu S, Wang H, Yao X. CALD1 promotes the expression of PD-L1 in bladder cancer via the JAK/STAT signaling pathway. Ann Transl Med 2021;9:1441. [PMID: 34733993 DOI: 10.21037/atm-21-4192] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 94 |
Han Y, Liu D, Li L. Increased expression of TAZ and associated upregulation of PD-L1 in cervical cancer. Cancer Cell Int 2021;21:592. [PMID: 34736474 DOI: 10.1186/s12935-021-02287-y] [Reference Citation Analysis]
|
| 95 |
Al-Salama ZT. Durvalumab: A Review in Extensive-Stage SCLC. Target Oncol 2021;16:857-64. [PMID: 34731446 DOI: 10.1007/s11523-021-00843-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 96 |
Shao B, Dang Q, Chen Z, Chen C, Zhou Q, Qiao B, Liu J, Hu S, Wang G, Yuan W, Sun Z. Effects of Tumor-Derived Exosome Programmed Death Ligand 1 on Tumor Immunity and Clinical Applications. Front Cell Dev Biol 2021;9:760211. [PMID: 34722545 DOI: 10.3389/fcell.2021.760211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 97 |
Wu Z, Chen L, Jin C, Xu J, Zhang X, Yao Y. A novel pyroptosis-associated gene signature for immune status and prognosis of cutaneous melanoma. PeerJ 2021;9:e12304. [PMID: 34721986 DOI: 10.7717/peerj.12304] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 98 |
Таширева Л, Муравьева Д, Попова Н, Гольдберг В, Вторушин С, Перельмутер В. Параметры микроокружения опухоли определяют эффективность анти-PD-1/PD-L1-терапии. БМ 2021;86:1677-1686. [DOI: 10.31857/s0320972521110063] [Reference Citation Analysis]
|
| 99 |
Tashireva LA, Muravyova DT, Popova NO, Goldberg VE, Vtorushin SV, Perelmuter VM. Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy. Biochemistry (Mosc) 2021;86:1461-8. [PMID: 34906044 DOI: 10.1134/S0006297921110092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 100 |
Zhou LQ, Li SH, Wu Y, Xin L. Establishment of a prognostic model of ten transcription factors in gastric cancer. Genomics 2021;113:4075-87. [PMID: 34688795 DOI: 10.1016/j.ygeno.2021.10.009] [Reference Citation Analysis]
|
| 101 |
Zhang Y, Chen X, Zheng H, Zhan Y, Luo J, Yang Y, Ning Y, Wang H, Wang W, Fan S. Expression of cancer cell-intrinsic PD-1 associates with PD-L1 and p-S6 and predicts a good prognosis in nasopharyngeal carcinoma. J Cancer 2021;12:6118-25. [PMID: 34539884 DOI: 10.7150/jca.60739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 102 |
Halim F, Agustina H, Azhar Y, Hernowo B. Programmed death ligand-1 protein expression difference in basal like and non-basal like triple negative breast cancer and its association with disease free survival and overall survival: A systematic review. Oncol Rev 2021;15:533. [PMID: 34703525 DOI: 10.4081/oncol.2021.533] [Reference Citation Analysis]
|
| 103 |
Zhang X, Liu Z, Hou Y, Jiao H, Ren J, Wang G. EV PD-L1 Contributes to Immunosuppressive CD8+ T Cells in Peripheral Blood of Pediatric Wilms Tumor. Technol Cancer Res Treat 2021;20:15330338211041264. [PMID: 34519584 DOI: 10.1177/15330338211041264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 104 |
Koh SA. An update on immunotherapy with PD-1 and PD-L1 blockade. Yeungnam Univ J Med 2021. [PMID: 34496466 DOI: 10.12701/yujm.2021.01312] [Reference Citation Analysis]
|
| 105 |
Cui H, Li Y, Li S, Liu G. Prognostic Function of Programmed Cell Death-Ligand 1 in Esophageal Squamous Cell Carcinoma Patients Without Preoperative Therapy: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:693886. [PMID: 34490091 DOI: 10.3389/fonc.2021.693886] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 106 |
Tan L, Cheng D, Wen J, Huang K, Zhang Q. Identification of prognostic hypoxia-related genes signature on the tumor microenvironment in esophageal cancer. Math Biosci Eng 2021;18:7743-58. [PMID: 34814273 DOI: 10.3934/mbe.2021384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 107 |
Adorisio S, Cannarile L, Delfino DV, Ayroldi E. Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused? Cells 2021;10:2333. [PMID: 34571982 DOI: 10.3390/cells10092333] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 108 |
Glorieux C, Xia X, Huang P. The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer. Cancers (Basel) 2021;13:4426. [PMID: 34503236 DOI: 10.3390/cancers13174426] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 109 |
Kulikov A, Shipaeva E, Dmitrieva A, Batrak V, Shipunov G, Guy C, Smith J, Zhang R, Zhang M, Duan J, Chestukhin A, Barbashov S, Samsonov M, Lavrovsky Y. Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120. Front Pharmacol 2021;12:723038. [PMID: 34456733 DOI: 10.3389/fphar.2021.723038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 110 |
Liu SR, Yan Q, Lin HM, Shi GZ, Cao Y, Zeng H, Liu C, Zhang R. Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports. World J Clin Cases 2021; 9(21): 5988-5998 [PMID: 34368318 DOI: 10.12998/wjcc.v9.i21.5988] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 111 |
Radanova M, Mihaylova G, Nazifova-Tasinova N, Levkova M, Tasinov O, Ivanova D, Mihaylova Z, Donev I. Oncogenic Functions and Clinical Significance of Circular RNAs in Colorectal Cancer. Cancers (Basel) 2021;13:3395. [PMID: 34298612 DOI: 10.3390/cancers13143395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 112 |
Jeong S, Park E, Kim HD, Sung E, Kim H, Jeon J, Kim Y, Jung UJ, Son YG, Hong Y, Lee H, Lee S, Lim Y, Won J, Jeon M, Hwang S, Fang L, Jiang W, Wang Z, Shin EC, Park SH, Jung J. Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade. J Immunother Cancer 2021;9:e002428. [PMID: 34230109 DOI: 10.1136/jitc-2021-002428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 113 |
Yu M, Zhao H, Miao Y, Luo SZ, Xue S. Virtual Evolution of HVEM Segment for Checkpoint Inhibitor Discovery. Int J Mol Sci 2021;22:6638. [PMID: 34205742 DOI: 10.3390/ijms22126638] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 114 |
Kim DH, Bae GE, Suh KS, Ryuman D, Song KS, Kim JS, Lee SI, Yeo MK. Clinical Significance of Tumor and Immune Cell PD-L1 Expression in Gastric Adenocarcinoma. In Vivo 2020;34:3171-80. [PMID: 33144421 DOI: 10.21873/invivo.12152] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 115 |
Lee K, Choi YJ, Kim JS, Kim DS, Lee SY, Shin BK, Kang EJ. Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications. Thorac Cancer 2021;12:2143-50. [PMID: 34121347 DOI: 10.1111/1759-7714.14006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 116 |
Guénolé M, Bénigni P, Bourbonne V, Lucia F, Legoupil D, Pradier O, Misery L, Uguen A, Schick U. The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma. J Cancer Res Clin Oncol 2021;147:2569-78. [PMID: 34115240 DOI: 10.1007/s00432-021-03676-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 117 |
Samir A, Tawab RA, Eltayebi HM. Long non-coding RNAs XIST and MALAT1 hijack the PD-L1 regulatory signaling pathway in breast cancer subtypes. Oncol Lett 2021;22:593. [PMID: 34149904 DOI: 10.3892/ol.2021.12854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 118 |
Feng ZY, Gao HY, Feng TD. Immune Infiltrates of m6A RNA Methylation-Related lncRNAs and Identification of PD-L1 in Patients With Primary Head and Neck Squamous Cell Carcinoma. Front Cell Dev Biol 2021;9:672248. [PMID: 34178999 DOI: 10.3389/fcell.2021.672248] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 119 |
Liu Q, Jiang L, Li K, Li H, Lv G, Lin J, Qiu L. Immuno-PET imaging of (68)Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers. Cancer Immunol Immunother 2021;70:1721-33. [PMID: 33386467 DOI: 10.1007/s00262-020-02818-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 120 |
Li Z, Fitzsimons HL, Hale TK, Park JH. EP400NL is required for cMyc-mediated PD-L1 gene activation by forming a transcriptional coactivator complex.. [DOI: 10.1101/2021.05.30.446361] [Reference Citation Analysis]
|
| 121 |
Wang Y, Lin R, Zhang B, Zhou H, Lin Z, Yao T. Pembrolizumab in FIGO IVB Verrucous Carcinoma of the Vulva: A Case Report. Front Oncol 2021;11:598594. [PMID: 34123775 DOI: 10.3389/fonc.2021.598594] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 122 |
Yu J, Wang Q, Zhang X, Guo Z, Cui X. Mechanisms of Neoantigen-Targeted Induction of Pyroptosis and Ferroptosis: From Basic Research to Clinical Applications. Front Oncol 2021;11:685377. [PMID: 34123855 DOI: 10.3389/fonc.2021.685377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 123 |
Shen L, Guo J, Zhang Q, Pan H, Yuan Y, Bai Y, Liu T, Zhou Q, Zhao J, Shu Y, Huang X, Wang S, Wang J, Zhou A, Ye D, Sun T, Gao Y, Yang S, Wang Z, Li J, Wu YL. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. J Immunother Cancer 2020;8:e000437. [PMID: 32561638 DOI: 10.1136/jitc-2019-000437] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 21.5] [Reference Citation Analysis]
|
| 124 |
Zhang F, Ferrero M, Dong N, D'Auria G, Reyes-Prieto M, Herreros-Pomares A, Calabuig-Fariñas S, Duréndez E, Aparisi F, Blasco A, García C, Camps C, Jantus-Lewintre E, Sirera R. Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:2514. [PMID: 34063829 DOI: 10.3390/cancers13112514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 125 |
Glover M, Avraamides S, Maher J. How Can We Engineer CAR T Cells to Overcome Resistance? Biologics 2021;15:175-98. [PMID: 34040345 DOI: 10.2147/BTT.S252568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 126 |
Wang Y, Gu T, Tian X, Li W, Zhao R, Yang W, Gao Q, Li T, Shim JH, Zhang C, Liu K, Lee MH. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. Front Immunol 2021;12:654463. [PMID: 34054817 DOI: 10.3389/fimmu.2021.654463] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 127 |
Luo, Kuang F, Du J, Zhou M, Peng F, Gan Y, Fang C, Yang X, Li B, Su S. Characterization of the Immune Cell Infiltration Profile in Pancreatic Carcinoma to Aid in Immunotherapy. Front Oncol 2021;11:677609. [PMID: 34055645 DOI: 10.3389/fonc.2021.677609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 128 |
Mizukami K, Sakata Y, Seo K, Kitamoto S, Mura T, Kikkawa A, Hiraki K. Multicenter Joint Retrospective Study on the Onset of Immune-related Adverse Events by TPS in Patients Indicated for Non-small Cell Lung Cancer Pembrolizumab Monotherapy. Jpn J Pharm Health Care Sci 2021;47:239-249. [DOI: 10.5649/jjphcs.47.239] [Reference Citation Analysis]
|
| 129 |
Berland L, Kim L, Abousaway O, Mines A, Mishra S, Clark L, Hofman P, Rashidian M. Nanobodies for Medical Imaging: About Ready for Prime Time? Biomolecules 2021;11:637. [PMID: 33925941 DOI: 10.3390/biom11050637] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 130 |
Garofalo M, Bertinato L, Staniszewska M, Wieczorek M, Salmaso S, Schrom S, Rinner B, Pancer KW, Kuryk L. Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model. Pharmaceutics 2021;13:547. [PMID: 33919827 DOI: 10.3390/pharmaceutics13040547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 131 |
Kwiecień I, Rutkowska E, Polubiec-Kownacka M, Raniszewska A, Rzepecki P, Domagała-Kulawik J. Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry. Transl Lung Cancer Res 2021;10:1679-89. [PMID: 34012784 DOI: 10.21037/tlcr-20-1103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 132 |
Li G, Wang G, Chi F, Jia Y, Wang X, Mu Q, Qin K, Zhu X, Pang J, Xu B, Feng G, Niu Y, Gong T, Zhang H, Dong X, Liu T, Ma J, Gao Z, Tao K, Li F, Xu J, Yu B. Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer. J Immunother Cancer 2021;9:e002218. [PMID: 33753568 DOI: 10.1136/jitc-2020-002218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 133 |
Moazzam P, Myekhlai M, Alinezhad A, Alshawawreh FA, Bakthavathsalam P, Gonçales VR, Tilley RD, Gooding JJ. Ultrasensitive detection of programmed death-ligand 1 (PD-L1) in whole blood using dispersible electrodes. Chem Commun (Camb) 2021;57:2559-62. [PMID: 33586712 DOI: 10.1039/d0cc08068c] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 134 |
Dickinson SE, Khawam M, Kirschnerova V, Vaishampayan P, Centuori SM, Saboda K, Calvert VS, Petricoin EF 3rd, Curiel-Lewandrowski C. Increased PD-L1 Expression in Human Skin Acutely and Chronically Exposed to UV Irradiation. Photochem Photobiol 2021;97:778-84. [PMID: 33615483 DOI: 10.1111/php.13406] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 135 |
Aló PL, Cicciarelli M, De Felice F, Quintiliani C, Corsi A, Polimeni A. Immunohistochemical Differences in Squamous Precancerous and Cancerous Lesions of the Oral Cavity and the Larynx: Preliminary Data. Applied Sciences 2021;11:2048. [DOI: 10.3390/app11052048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 136 |
Zhang D, Reyes RM, Osta E, Kari S, Gupta HB, Padron AS, Kornepati AVR, Kancharla A, Sun X, Deng Y, Wu B, Vadlamudi R, Li R, Svatek RS, Curiel TJ. Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. Cancer Med 2021;10:2137-52. [PMID: 33626233 DOI: 10.1002/cam4.3739] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 137 |
Ehrlich M, Bacharach E. Oncolytic Virotherapy: The Cancer Cell Side. Cancers (Basel) 2021;13:939. [PMID: 33668131 DOI: 10.3390/cancers13050939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 138 |
Sefid F, Payandeh Z, Azamirad G, Baradaran B, Nabi Afjadi M, Islami M, Darvish M, Kalantar SM, Kahroba H, Ardakani MA. Atezolizumab and granzyme B as immunotoxin against PD-L1 antigen; an insilico study. In Silico Pharmacol 2021;9:20. [PMID: 33680705 DOI: 10.1007/s40203-021-00076-z] [Reference Citation Analysis]
|
| 139 |
Gameiro A, Nascimento C, Urbano AC, Correia J, Ferreira F. Serum and Tissue Expression Levels of Leptin and Leptin Receptor Are Putative Markers of Specific Feline Mammary Carcinoma Subtypes. Front Vet Sci 2021;8:625147. [PMID: 33644151 DOI: 10.3389/fvets.2021.625147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 140 |
Qiu Z, Du Y. Clinicopathological and prognostic significance of programmed death ligant-1 expression in gastric cancer: a meta-analysis. J Gastrointest Oncol 2021;12:112-20. [PMID: 33708429 DOI: 10.21037/jgo-20-568] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 141 |
Kim W, Chu TH, Nienhüser H, Jiang Z, Del Portillo A, Remotti HE, White RA, Hayakawa Y, Tomita H, Fox JG, Drake CG, Wang TC. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice. Gastroenterology 2021;160:781-96. [PMID: 33129844 DOI: 10.1053/j.gastro.2020.10.036] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 18.5] [Reference Citation Analysis]
|
| 142 |
Mansour MSI, Seidal T, Mager U, Dobra K, Brunnström H, Dejmek A. Higher concordance of PD-L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma. Cancer Cytopathol 2021;129:468-78. [PMID: 33493383 DOI: 10.1002/cncy.22401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 143 |
Nandi D, Pathak S, Verma T, Singh M, Chattopadhyay A, Thakur S, Raghavan A, Gokhroo A, Vijayamahantesh. T cell costimulation, checkpoint inhibitors and anti-tumor therapy. J Biosci. 2020;45. [PMID: 32345776 DOI: 10.1007/s12038-020-0020-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 144 |
Huang HW, Chang CC, Wang CS, Lin KH. Association between Inflammation and Function of Cell Adhesion Molecules Influence on Gastrointestinal Cancer Development. Cells 2021;10:E67. [PMID: 33406733 DOI: 10.3390/cells10010067] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 145 |
Hu X, Wang J, Chu M, Liu Y, Wang ZW, Zhu X. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy. Mol Ther 2021;29:908-19. [PMID: 33388422 DOI: 10.1016/j.ymthe.2020.12.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 146 |
齐 甜. Clinical Observation of Sintilimab in the Treatment of Advanced Non-Small Cell Lung Cancer. ACM 2021;11:5625-5630. [DOI: 10.12677/acm.2021.1112833] [Reference Citation Analysis]
|
| 147 |
Koutsoumpli G, Draghiciu O, Nijman HW, Oyarce C, Daemen T. Strategies to Target Tumor Immunosuppression. Cancer Immunology 2021. [DOI: 10.1007/978-3-030-50287-4_5] [Reference Citation Analysis]
|
| 148 |
Wang L, Liu Y, Liu H, Tian H, Wang Y, Zhang G, Lei Y, Xue L, Zheng B, Fan T, Zheng Y, Tan F, Xue Q, Gao S, Li C, He J. The therapeutic significance of the novel photodynamic material TPE-IQ-2O in tumors. Aging (Albany NY) 2020;13:1383-409. [PMID: 33472175 DOI: 10.18632/aging.202355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 149 |
Filin IY, Solovyeva VV, Kitaeva KV, Rutland CS, Rizvanov AA. Current Trends in Cancer Immunotherapy. Biomedicines 2020;8:E621. [PMID: 33348704 DOI: 10.3390/biomedicines8120621] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 150 |
Castro-Sanchez P, Teagle AR, Prade S, Zamoyska R. Modulation of TCR Signaling by Tyrosine Phosphatases: From Autoimmunity to Immunotherapy. Front Cell Dev Biol 2020;8:608747. [PMID: 33425916 DOI: 10.3389/fcell.2020.608747] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 151 |
Huang J, Teng X. Expression of PD-L1 for predicting response to immune checkpoint inhibitors in metastatic urothelial carcinoma: a systematic review and meta-analysis. Curr Oncol 2020;27:e656-63. [PMID: 33380881 DOI: 10.3747/co.27.6437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 152 |
Theodoraki M, Ludwig S. Exosomen: potenzielle Flüssigbiopsie bei Kopf-Hals-Karzinomen. best practice onkologie 2020;15:520-526. [DOI: 10.1007/s11654-020-00273-w] [Reference Citation Analysis]
|
| 153 |
Khasraw M, Walsh KM, Heimberger AB, Ashley DM. What is the Burden of Proof for Tumor Mutational Burden in gliomas? Neuro Oncol 2020:noaa256. [PMID: 33252666 DOI: 10.1093/neuonc/noaa256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 154 |
Evrard D, Hourseau M, Couvelard A, Paradis V, Gauthier H, Raymond E, Halimi C, Barry B, Faivre S. PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma. Oncoimmunology 2020;9:1844403. [PMID: 33299655 DOI: 10.1080/2162402X.2020.1844403] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 155 |
Choi JG, Kim YS, Kim JH, Kim TI, Li W, Oh TW, Jeon CH, Kim SJ, Chung HS. Anticancer Effect of Salvia plebeia and Its Active Compound by Improving T-Cell Activity via Blockade of PD-1/PD-L1 Interaction in Humanized PD-1 Mouse Model. Front Immunol 2020;11:598556. [PMID: 33224152 DOI: 10.3389/fimmu.2020.598556] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 156 |
White MG, Schulte JJ, Xue L, Berger Y, Schuitevoerder D, Vining CC, Kindler HL, Husain A, Turaga KK, Eng OS. Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br J Cancer 2021;124:564-6. [PMID: 33100328 DOI: 10.1038/s41416-020-01130-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 157 |
Qin Y, Jiang L, Yu M, Li Y, Zhou X, Wang Y, Gong Y, Peng F, Zhu J, Liu Y, Xu Y, Zhou L, Lu Y, Huang M. PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy. Sci Rep 2020;10:16150. [PMID: 32999345 DOI: 10.1038/s41598-020-73013-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 158 |
Lotfinejad P, Asghari Jafarabadi M, Abdoli Shadbad M, Kazemi T, Pashazadeh F, Sandoghchian Shotorbani S, Jadidi Niaragh F, Baghbanzadeh A, Vahed N, Silvestris N, Baradaran B. Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study. Diagnostics (Basel) 2020;10:E704. [PMID: 32957579 DOI: 10.3390/diagnostics10090704] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 159 |
Miller PL, Carson TL. Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review. Gut Pathog 2020;12. [DOI: 10.1186/s13099-020-00381-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 160 |
Wang L, Hu Y, Wang S, Shen J, Wang X. Biomarkers of immunotherapy in non-small cell lung cancer. Oncol Lett 2020;20:139. [PMID: 32934707 DOI: 10.3892/ol.2020.11999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 161 |
Cangelosi D, Morini M, Zanardi N, Sementa AR, Muselli M, Conte M, Garaventa A, Pfeffer U, Bosco MC, Varesio L, Eva A. Hypoxia Predicts Poor Prognosis in Neuroblastoma Patients and Associates with Biological Mechanisms Involved in Telomerase Activation and Tumor Microenvironment Reprogramming. Cancers (Basel) 2020;12:E2343. [PMID: 32825087 DOI: 10.3390/cancers12092343] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 162 |
Raimondi A, Sepe P, Zattarin E, Mennitto A, Stellato M, Claps M, Guadalupi V, Verzoni E, de Braud F, Procopio G. Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. Front Oncol 2020;10:1644. [PMID: 32903369 DOI: 10.3389/fonc.2020.01644] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 163 |
Wirta EV, Szeto S, Hänninen U, Ahtiainen M, Böhm J, Mecklin JP, Aaltonen LA, Seppälä TT. Prognostic Value of Immune Environment Analysis in Small Bowel Adenocarcinomas with Verified Mutational Landscape and Predisposing Conditions. Cancers (Basel) 2020;12:E2018. [PMID: 32718028 DOI: 10.3390/cancers12082018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 164 |
Mohammadzadeh S, Khanahmad H, Esmaeil N, Eskandari N, Rahimmanesh I, Rezaei A, Andalib A. Producing Soluble Human Programmed Cell Death Protein-1: A Natural Supporter for CD4+T Cell Cytotoxicity and Tumor Cells Apoptosis. Iran J Biotechnol 2019;17:e2104. [PMID: 32671122 DOI: 10.30498/IJB.2019.85180] [Reference Citation Analysis]
|
| 165 |
Sancakli Usta C, Altun E, Afsar S, Bulbul CB, Usta A, Adalı E. Overexpression of programmed cell death ligand 1 in patients with CIN and its correlation with human papillomavirus infection and CIN persistence. Infect Agent Cancer 2020;15:47. [PMID: 32695218 DOI: 10.1186/s13027-020-00312-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 166 |
Nowak Ł, Krajewski W, Poterek A, Śliwa A, Zdrojowy R. The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette-Guérin immunotherapy: Current status. Arab J Urol 2020;19:67-70. [PMID: 33763250 DOI: 10.1080/2090598X.2020.1791562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 167 |
Guida M, D'Alò A, Mangia A, Di Pinto F, Sonnessa M, Albano A, Sciacovelli A, Asabella AN, Fucci L. Somatostatin Receptors in Merkel-Cell Carcinoma: A Therapeutic Opportunity Using Somatostatin Analog Alone or in Association With Checkpoint Inhibitors Immunotherapy. A Case Report. Front Oncol 2020;10:1073. [PMID: 32733801 DOI: 10.3389/fonc.2020.01073] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 168 |
Zhong L, Altan M, Shannon VR, Sheshadri A. Immune-Related Adverse Events: Pneumonitis. Adv Exp Med Biol 2020;1244:255-69. [PMID: 32301020 DOI: 10.1007/978-3-030-41008-7_13] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 169 |
Allouch S, Malki A, Allouch A, Gupta I, Vranic S, Al Moustafa AE. High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions. Front Oncol 2020;10:914. [PMID: 32695664 DOI: 10.3389/fonc.2020.00914] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 170 |
Papalexi E, Mimitou E, Butler AW, Foster S, Bracken B, Mauck WM, Wessels H, Yeung BZ, Smibert P, Satija R. Characterizing the molecular regulation of inhibitory immune checkpoints with multi-modal single-cell screens.. [DOI: 10.1101/2020.06.28.175596] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 171 |
Dave K, Ali A, Magalhaes M. Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study. Sci Rep 2020;10:9705. [PMID: 32546692 DOI: 10.1038/s41598-020-66257-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 172 |
Chew M, Wong YP, Karim N, Mustangin M, Alfian N, Tan GC. Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma. Diagnostics (Basel) 2020;10:E394. [PMID: 32545177 DOI: 10.3390/diagnostics10060394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 173 |
Olbryt M, Rajczykowski M, Widłak W. Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors. Int J Mol Sci 2020;21:E4071. [PMID: 32517213 DOI: 10.3390/ijms21114071] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 174 |
Choi E, Chang MS, Byeon SJ, Jin H, Jung KC, Kim H, Lee KL, Kim W, Park JH, Kim KH, Kim JS, Choi IS, Han DS, Ahn HS, Heo SC. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas. Diagn Pathol 2020;15:69. [PMID: 32498695 DOI: 10.1186/s13000-020-00979-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 175 |
Ling B, Huang Z, Huang S, Qian L, Li G, Tang Q. Microenvironment Analysis of Prognosis and Molecular Signature of Immune-Related Genes in Lung Adenocarcinoma. Oncol Res 2021;28:561-78. [PMID: 32471520 DOI: 10.3727/096504020X15907428281601] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 176 |
Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020;6:38. [PMID: 32382051 DOI: 10.1038/s41572-020-0160-6] [Cited by in Crossref: 399] [Cited by in F6Publishing: 396] [Article Influence: 133.0] [Reference Citation Analysis]
|
| 177 |
Lérias S, Esteves S, Silva F, Cunha M, Cochicho D, Martins L, Félix A. CD274 (PD-L1), CDKN2A (p16), TP53, and EGFR immunohistochemical profile in primary, recurrent and metastatic vulvar cancer. Mod Pathol 2020;33:893-904. [PMID: 31844270 DOI: 10.1038/s41379-019-0429-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 178 |
Gameiro A, Nascimento C, Urbano AC, Correia J, Ferreira F. Serum levels and tumour expression of leptin and leptin receptor as promising clinical biomarkers of specific feline mammary carcinoma subtypes.. [DOI: 10.1101/2020.04.27.064600] [Reference Citation Analysis]
|
| 179 |
Vargas AC, Maclean FM, Sioson L, Tran D, Bonar F, Mahar A, Cheah AL, Russell P, Grimison P, Richardson L, Gill AJ. Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes. PLoS One 2020;15:e0222551. [PMID: 32294103 DOI: 10.1371/journal.pone.0222551] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 180 |
Badiyan S, Kaiser A, Eastman B, Forsthoefel M, Zeng J, Unger K, Chuong M. Immunotherapy and radiation therapy for gastrointestinal malignancies: hope or hype? Transl Gastroenterol Hepatol 2020;5:21. [PMID: 32258525 DOI: 10.21037/tgh.2019.10.07] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 181 |
Alburquerque-González B, López-Calderón FF, López-Abellán MD, Esteban-Gil Á, García-Solano J, Conesa-Zamora P. Biology and Therapeutic Targets of Colorectal Serrated Adenocarcinoma; Clues for a Histologically Based Treatment against an Aggressive Tumor. Int J Mol Sci 2020;21:E1991. [PMID: 32183342 DOI: 10.3390/ijms21061991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 182 |
Klose J, Lasitschka F, Horsch C, Strowitzki MJ, Bruckner T, Volz C, Schmidt T, Schneider M. Prognostic relevance of programmed death-ligand 1 expression and microsatellite status in small bowel adenocarcinoma. Scand J Gastroenterol 2020;55:321-9. [PMID: 32191146 DOI: 10.1080/00365521.2020.1734073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 183 |
Kim JH, Kim K, Kim M, Kim YM, Suh JH, Cha HJ, Choi HJ. Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer. J Pathol Transl Med 2020;54:154-64. [PMID: 32028754 DOI: 10.4132/jptm.2019.11.13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 184 |
Pierconti F, Raspollini MR, Martini M, Larocca LM, Bassi PF, Bientinesi R, Baroni G, Minervini A, Petracco G, Pini GM, Patriarca C. PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders. Virchows Arch 2020;477:269-77. [PMID: 32034486 DOI: 10.1007/s00428-020-02755-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 185 |
Zuo S, Sho M, Sawai T, Kanehiro H, Maeda K, Yoshida M, Tsukada R, Nomura M, Okuyama H. Potential role of the PD-L1 expression and tumor-infiltrating lymphocytes on neuroblastoma. Pediatr Surg Int 2020;36:137-43. [PMID: 31925505 DOI: 10.1007/s00383-019-04616-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 186 |
Li G, Wang G, Chi F, Jia Y, Wang X, Qin K, Zhu X, Pang J, Xu B, Feng G, Niu Y, Gong T, Zhang H, Dong X, Liu T, Ma J, Gao Z, Tao K, Li F, Yu B, Xu J. Higher Post-Operative Plasma EV PD-L1 Predicts Poor Survival in Gastric Cancer Patients. SSRN Journal. [DOI: 10.2139/ssrn.3738649] [Reference Citation Analysis]
|
| 187 |
Peng YZ, Yang LJ, Lo HH, Law BYK, Wong VKW. Tumor Therapeutic Modes. New Nanomaterials and Techniques for Tumor-targeted Systems 2020. [DOI: 10.1007/978-981-15-5159-8_6] [Reference Citation Analysis]
|
| 188 |
Wilczyński JR, Nowak M, Wilczyński M. Immunology and Immunotherapy of Ovarian Cancer. Cancer Immunology 2020. [DOI: 10.1007/978-3-030-57949-4_20] [Reference Citation Analysis]
|
| 189 |
Pan MR, Wu CC, Kan JY, Li QL, Chang SJ, Wu CC, Li CL, Ou-Yang F, Hou MF, Yip HK, Luo CW. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer. Cancers (Basel) 2019;12:E94. [PMID: 31905966 DOI: 10.3390/cancers12010094] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 190 |
Osei E, Walters P, Masella O, Tennant Q, Fishwick A, Dadzie E, Bhangu A, Darko J. A review of predictive, prognostic and diagnostic biomarkers for brain tumours: towards personalised and targeted cancer therapy. J Radiother Pract 2021;20:83-98. [DOI: 10.1017/s1460396919000955] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 191 |
Liu X, He S, Wu H, Xie H, Zhang T, Deng Z. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo. Environ Health Prev Med 2019;24:79. [PMID: 31864288 DOI: 10.1186/s12199-019-0835-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 192 |
Nguyen HD, Liao YC, Ho YS, Chen LC, Chang HW, Cheng TC, Liu D, Lee WR, Shen SC, Wu CH, Tu SH. The α9 Nicotinic Acetylcholine Receptor Mediates Nicotine-Induced PD-L1 Expression and Regulates Melanoma Cell Proliferation and Migration. Cancers (Basel) 2019;11:E1991. [PMID: 31835799 DOI: 10.3390/cancers11121991] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 193 |
Zhou Y, Zhu Y, Xie Y, Ma X. The Role of Long Non-coding RNAs in Immunotherapy Resistance. Front Oncol 2019;9:1292. [PMID: 31850199 DOI: 10.3389/fonc.2019.01292] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 194 |
Huyghe N, Baldin P, Van den Eynde M. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? Gastroenterol Rep (Oxf) 2020;8:11-24. [PMID: 32104582 DOI: 10.1093/gastro/goz061] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 195 |
Higuchi R, Goto T, Hirotsu Y, Nakagomi T, Yokoyama Y, Otake S, Amemiya K, Oyama T, Omata M. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms. J Clin Med 2019;8:E1833. [PMID: 31683962 DOI: 10.3390/jcm8111833] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 196 |
Li C, Li C, Zhi C, Liang W, Wang X, Chen X, Lv T, Shen Q, Song Y, Lin D, Liu H. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. J Transl Med 2019;17:355. [PMID: 31665020 DOI: 10.1186/s12967-019-2101-2] [Cited by in Crossref: 84] [Cited by in F6Publishing: 89] [Article Influence: 21.0] [Reference Citation Analysis]
|
| 197 |
Saleh R, Toor SM, Khalaf S, Elkord E. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells. Vaccines (Basel) 2019;7:E149. [PMID: 31614877 DOI: 10.3390/vaccines7040149] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 198 |
Young K, Friedman E. Lung Carcinoma Presenting as a Superior Vena Cava Syndrome, Burnt and Twice Reborn as Adrenal and Facial Tumors. Cureus 2019;11:e5746. [PMID: 31723507 DOI: 10.7759/cureus.5746] [Reference Citation Analysis]
|
| 199 |
Liao XY, Liu CY, He JF, Wang LS, Zhang T. Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy. Oncol Lett 2019;18:5011-21. [PMID: 31612012 DOI: 10.3892/ol.2019.10893] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 200 |
Seliger B. The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment-Review. Front Immunol 2019;10:2043. [PMID: 31555274 DOI: 10.3389/fimmu.2019.02043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 201 |
Vargas AC, Maclean FM, Sioson L, Tran D, Bonar F, Mahar A, Cheah AL, Russell P, Grimison P, Richardson L, Gill AJ. PD-L1 expression in 522 selected sarcomas with subset analysis of recurrent or metastatic matched samples and association with tumour-infiltrating lymphocytes.. [DOI: 10.1101/757625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 202 |
Shindo Y, Hazama S, Tsunedomi R, Suzuki N, Nagano H. Novel Biomarkers for Personalized Cancer Immunotherapy. Cancers (Basel) 2019;11:E1223. [PMID: 31443339 DOI: 10.3390/cancers11091223] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 203 |
Ajina R, Zamalin D, Weiner LM. Functional genomics: paving the way for more successful cancer immunotherapy. Brief Funct Genomics 2019;18:86-98. [PMID: 29762641 DOI: 10.1093/bfgp/ely017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 204 |
Haymond A, Davis JB, Espina V. Proteomics for cancer drug design. Expert Rev Proteomics 2019;16:647-64. [PMID: 31353977 DOI: 10.1080/14789450.2019.1650025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 205 |
Saleh R, Taha RZ, Sasidharan Nair V, Alajez NM, Elkord E. PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer. Cancers (Basel) 2019;11:E1050. [PMID: 31349612 DOI: 10.3390/cancers11081050] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 206 |
Lux A, Kahlert C, Grützmann R, Pilarsky C. c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer. Int J Mol Sci 2019;20:E3305. [PMID: 31284422 DOI: 10.3390/ijms20133305] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 18.3] [Reference Citation Analysis]
|
| 207 |
Tabares T, Unmack T, Calys M, Stehno-bittel L. New Anticancer Immunotherapies: Implications for Physical Therapy. Rehabilitation Oncology 2019;37:128-137. [DOI: 10.1097/01.reo.0000000000000144] [Reference Citation Analysis]
|
| 208 |
Gilmore E, McCabe N, Kennedy RD, Parkes EE. DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. J Oncol 2019;2019:4325105. [PMID: 31320901 DOI: 10.1155/2019/4325105] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 209 |
Kotsakis A, Kallergi G, Aggouraki D, Lyristi Z, Koinis F, Lagoudaki E, Koutsopoulos A, Georgoulias V, Vetsika EK. CD8+ PD-1+ T-cells and PD-L1+ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance? Ther Adv Med Oncol 2019;11:1758835919853193. [PMID: 31217824 DOI: 10.1177/1758835919853193] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 210 |
Huang ZL, Liu S, Wang GN, Zheng SH, Ding SR, Tao YL, Chen C, Liu SR, Yang X, Chang H, Wang XH, Xia YF. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Cancer Cell Int 2019;19:141. [PMID: 31139018 DOI: 10.1186/s12935-019-0863-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 211 |
Aung PP, Sukswai N, Nejati R, Loghavi S, Chen W, Torres-Cabala CA, Yin CC, Konopleva M, Zheng X, Wang J, Tang Z, Medeiros LJ, Prieto VG, Pemmaraju N, Khoury JD. PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 2019;11:E695. [PMID: 31109153 DOI: 10.3390/cancers11050695] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 212 |
Grochot RM, Brollo J, Neto FR, Tregnago AC, Scholze C, Norris R, Silva S, Weschenfelder DC, Reiriz AB, Michelin L, Pasqualotto FF. Expression of PD-L1 in cervical carcinoma and its impact on survival associated with T-cell infiltration and FoxP3 expression. Cancer Manag Res 2019;11:4597-605. [PMID: 31191020 DOI: 10.2147/CMAR.S194597] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 213 |
Jia Q, Wang J, He N, He J, Zhu B. Titin mutation associated with responsiveness to checkpoint blockades in solid tumors. JCI Insight. 2019;4:e127901. [PMID: 31092729 DOI: 10.1172/jci.insight.127901] [Cited by in Crossref: 54] [Cited by in F6Publishing: 66] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 214 |
Olbryt M. Molecular background of skin melanoma development and progression: therapeutic implications. Postepy Dermatol Alergol 2019;36:129-38. [PMID: 31320844 DOI: 10.5114/ada.2019.84590] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 215 |
Hou YC, Chao YJ, Hsieh MH, Tung HL, Wang HC, Shan YS. Low CD8⁺ T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44⁺/CD133⁺ Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer. Cancers (Basel) 2019;11:E541. [PMID: 30991694 DOI: 10.3390/cancers11040541] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 216 |
Yoshida K, Okamoto M, Sasaki J, Kuroda C, Ishida H, Ueda K, Okano S, Ideta H, Kamanaka T, Sobajima A, Takizawa T, Kito M, Aoki K, Uemura T, Haniu H, Kato H, Saito N. Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers. Onco Targets Ther 2019;12:2513-8. [PMID: 31040694 DOI: 10.2147/OTT.S198421] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 217 |
Sunami Y, Kleeff J. Immunotherapy of pancreatic cancer. Prog Mol Biol Transl Sci 2019;164:189-216. [PMID: 31383405 DOI: 10.1016/bs.pmbts.2019.03.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 218 |
Chen TW, Huang KC, Chiang SF, Chen WT, Ke TW, Chao KSC. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy. J Cancer Res Clin Oncol 2019;145:1043-53. [PMID: 30874889 DOI: 10.1007/s00432-019-02874-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 219 |
Orth MF, Buecklein VL, Kampmann E, Subklewe M, Noessner E, Cidre-aranaz F, Romero-pérez L, Wehweck FS, Lindner L, Issels R, Kirchner T, Altendorf-hofmann A, Grünewald TGP, Knösel T. Expression patterns of PD-L1 and PD-1 provide rationales for immune checkpoint inhibition in soft tissue sarcomas.. [DOI: 10.1101/569418] [Reference Citation Analysis]
|
| 220 |
Wang Y, Li G. PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. Front Med 2019;13:438-50. [PMID: 30826965 DOI: 10.1007/s11684-018-0674-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 221 |
Ando Y, Siegler EL, Ta HP, Cinay GE, Zhou H, Gorrell KA, Au H, Jarvis BM, Wang P, Shen K. Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model. Adv Healthc Mater 2019;8:e1900001. [PMID: 30734529 DOI: 10.1002/adhm.201900001] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 222 |
Gottlieb A, Best J, Canbay A. Implications of Immunotherapy in Hepatobiliary Tumors. Visc Med 2019;35:18-26. [PMID: 31312646 DOI: 10.1159/000496755] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 223 |
Liu GM, Li XG, Zhang YM. Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis. Cancer Cell Int 2019;19:22. [PMID: 30718977 DOI: 10.1186/s12935-019-0738-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 224 |
Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. J Immunother Cancer 2019;7:18. [PMID: 30678715 DOI: 10.1186/s40425-018-0489-5] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 14.3] [Reference Citation Analysis]
|
| 225 |
Pawłowska A, Suszczyk D, Okła K, Barczyński B, Kotarski J, Wertel I. Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment. Clin Exp Immunol 2019;195:334-44. [PMID: 30582756 DOI: 10.1111/cei.13255] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 226 |
Comito G, Iscaro A, Bacci M, Morandi A, Ippolito L, Parri M, Montagnani I, Raspollini MR, Serni S, Simeoni L, Giannoni E, Chiarugi P. Lactate modulates CD4+ T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis. Oncogene 2019;38:3681-95. [PMID: 30664688 DOI: 10.1038/s41388-019-0688-7] [Cited by in Crossref: 81] [Cited by in F6Publishing: 86] [Article Influence: 20.3] [Reference Citation Analysis]
|
| 227 |
Zhang M, Jiang H, Zhang R, Jiang H, Xu H, Pan W, Gao X, Sun Z. Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice. J Cell Biochem 2019;120:10239-47. [PMID: 30609118 DOI: 10.1002/jcb.28308] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 228 |
Yang JH, Kim H, Roh SY, Lee MA, Park JM, Lee HH, Park CH, Lee HH, Jung ES, Lee SH, Lee YJ, Choi MH, Kim O, Kim IH. Discordancy and changes in the pattern of programmed death ligand 1 expression before and after platinum-based chemotherapy in metastatic gastric cancer. Gastric Cancer 2019;22:147-54. [PMID: 29860599 DOI: 10.1007/s10120-018-0842-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 229 |
Cordes N, Görte J, Korovina I, Förster S. Signal Transduction in Radiation Oncology. Radiation Oncology 2019. [DOI: 10.1007/978-3-319-52619-5_112-1] [Reference Citation Analysis]
|
| 230 |
Sforzini L, Nettis MA, Mondelli V, Pariante CM. Inflammation in cancer and depression: a starring role for the kynurenine pathway. Psychopharmacology (Berl) 2019;236:2997-3011. [PMID: 30806743 DOI: 10.1007/s00213-019-05200-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 231 |
Osorio JC, Harding JJ. Understanding and quantifying the immune microenvironment in hepatocellular carcinoma. Transl Gastroenterol Hepatol 2018;3:107. [PMID: 30701214 DOI: 10.21037/tgh.2018.12.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 232 |
Collins JM, Gulley JL. Product review: avelumab, an anti-PD-L1 antibody. Hum Vaccin Immunother 2019;15:891-908. [PMID: 30481100 DOI: 10.1080/21645515.2018.1551671] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 233 |
Xia X, Zhou W, Guo C, Fu Z, Zhu L, Li P, Xu Y, Zheng L, Zhang H, Shan C, Gao Y. Glutaminolysis Mediated by MALT1 Protease Activity Facilitates PD-L1 Expression on ABC-DLBCL Cells and Contributes to Their Immune Evasion. Front Oncol 2018;8:632. [PMID: 30619766 DOI: 10.3389/fonc.2018.00632] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 234 |
Manson QF, Schrijver WAME, Ter Hoeve ND, Moelans CB, van Diest PJ. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases. Clin Exp Metastasis 2019;36:29-37. [PMID: 30547271 DOI: 10.1007/s10585-018-9950-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 235 |
Martin Lluesma S, Graciotti M, Chiang CL, Kandalaft LE. Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies? Vaccines (Basel) 2018;6:E79. [PMID: 30477198 DOI: 10.3390/vaccines6040079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 236 |
Jiang C, Zhu Y, Tang S, Zhang G, Lin Q, Xu Y, Shang J. High PD-L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy. Oncol Lett 2019;17:1626-34. [PMID: 30675222 DOI: 10.3892/ol.2018.9747] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 237 |
Koustas E, Papavassiliou AG, Karamouzis MV. The role of autophagy in the treatment of BRAF mutant colorectal carcinomas differs based on microsatellite instability status. PLoS One 2018;13:e0207227. [PMID: 30427914 DOI: 10.1371/journal.pone.0207227] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 238 |
Macherla S, Laks S, Naqash AR, Bulumulle A, Zervos E, Muzaffar M. Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. Int J Mol Sci 2018;19:E3505. [PMID: 30405053 DOI: 10.3390/ijms19113505] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 10.2] [Reference Citation Analysis]
|
| 239 |
Medina Enríquez MM, Félix AJ, Ciudad CJ, Noé V. Cancer immunotherapy using PolyPurine Reverse Hoogsteen hairpins targeting the PD-1/PD-L1 pathway in human tumor cells. PLoS One 2018;13:e0206818. [PMID: 30399174 DOI: 10.1371/journal.pone.0206818] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 240 |
Cheng WJ, Chen LC, Ho HO, Lin HL, Sheu MT. Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy. Int J Nanomedicine 2018;13:7079-94. [PMID: 30464460 DOI: 10.2147/IJN.S181440] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 241 |
Shirazi M, Sepulveda AR. Therapy Implications of DNA Mismatch Repair Deficiency, Microsatellite Instability, and Tumor Mutation Burden. Advances in Molecular Pathology 2018;1:193-208. [DOI: 10.1016/j.yamp.2018.07.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 242 |
Arulraj T, Barik D. Mathematical modeling identifies Lck as a potential mediator for PD-1 induced inhibition of early TCR signaling. PLoS One 2018;13:e0206232. [PMID: 30356330 DOI: 10.1371/journal.pone.0206232] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 243 |
Faure-Dupuy S, Durantel D, Lucifora J. Liver macrophages: Friend or foe during hepatitis B infection? Liver Int 2018;38:1718-29. [PMID: 29772112 DOI: 10.1111/liv.13884] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 244 |
Ng CW, Li J, Pu K. Recent Progresses in Phototherapy-Synergized Cancer Immunotherapy. Adv Funct Mater 2018;28:1804688. [DOI: 10.1002/adfm.201804688] [Cited by in Crossref: 175] [Cited by in F6Publishing: 181] [Article Influence: 35.0] [Reference Citation Analysis]
|
| 245 |
Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion. Front Oncol. 2018;8:386. [PMID: 30283733 DOI: 10.3389/fonc.2018.00386] [Cited by in Crossref: 126] [Cited by in F6Publishing: 139] [Article Influence: 25.2] [Reference Citation Analysis]
|
| 246 |
Sobral-Leite M, Van de Vijver K, Michaut M, van der Linden R, Hooijer GKJ, Horlings HM, Severson TM, Mulligan AM, Weerasooriya N, Sanders J, Glas AM, Wehkamp D, Mittempergher L, Kersten K, Cimino-Mathews A, Peters D, Hooijberg E, Broeks A, van de Vijver MJ, Bernards R, Andrulis IL, Kok M, de Visser KE, Schmidt MK. Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. Oncoimmunology 2018;7:e1509820. [PMID: 30524905 DOI: 10.1080/2162402X.2018.1509820] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 10.4] [Reference Citation Analysis]
|
| 247 |
De Sousa Linhares A, Leitner J, Grabmeier-Pfistershammer K, Steinberger P. Not All Immune Checkpoints Are Created Equal. Front Immunol 2018;9:1909. [PMID: 30233564 DOI: 10.3389/fimmu.2018.01909] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 248 |
Leone K, Poggiana C, Zamarchi R. The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy. Diagnostics (Basel) 2018;8:E59. [PMID: 30200242 DOI: 10.3390/diagnostics8030059] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 249 |
Rataj F, Kraus FBT, Chaloupka M, Grassmann S, Heise C, Cadilha BL, Duewell P, Endres S, Kobold S. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma. Front Immunol 2018;9:1955. [PMID: 30214445 DOI: 10.3389/fimmu.2018.01955] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 250 |
Sprague L, Braidwood L, Conner J, Cassady KA, Benencia F, Cripe TP. Please stand by: how oncolytic viruses impact bystander cells. Future Virol 2018;13:671-80. [PMID: 30416535 DOI: 10.2217/fvl-2018-0068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 251 |
Lee KS, Kim BH, Oh HK, Kim DW, Kang SB, Kim H, Shin E. Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer: Implications for prognosis. Cancer Sci 2018;109:2957-69. [PMID: 29949671 DOI: 10.1111/cas.13716] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 252 |
Arun AS, Tepper CG, Lam KS. Identification of integrin drug targets for 17 solid tumor types. Oncotarget 2018;9:30146-62. [PMID: 30046394 DOI: 10.18632/oncotarget.25731] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 253 |
Hammerbacher J, Snyder A. Informatics for cancer immunotherapy. Ann Oncol 2017;28:xii56-73. [PMID: 29253114 DOI: 10.1093/annonc/mdx682] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 254 |
Hsieh CC, Hsu HS, Li AF, Chen YJ. Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma. J Thorac Dis 2018;10:4433-44. [PMID: 30174892 DOI: 10.21037/jtd.2018.06.167] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 255 |
Ahmed MM, Ibrahim HM, Balata SA, Abdou AM. Expression of immunomodulator programmed death ligand 1 and fork head box protein 3 in squamous cell carcinoma of cervix. Egyptian Journal of Pathology 2018;38:52-60. [DOI: 10.1097/01.xej.0000534717.60403.bb] [Reference Citation Analysis]
|
| 256 |
Domingo-Musibay E, Murugan P, Giubellino A, Sharma S, Steinberger D, Yuan J, Hunt MA, Lou E, Miller JS. Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma. J Immunother Cancer 2018;6:58. [PMID: 29914578 DOI: 10.1186/s40425-018-0357-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 257 |
Bensaid D, Blondy T, Deshayes S, Dehame V, Bertrand P, Grégoire M, Errami M, Blanquart C. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma. Clin Epigenetics 2018;10:79. [PMID: 29946373 DOI: 10.1186/s13148-018-0517-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 258 |
Barnett CM, Sommerville RS, Lin C, Ratnayake G, Hughes B, Taheri T. CXCR4 and PD-1 Expression in Head and Neck Cancer with Perineural Spread. J Neurol Surg B Skull Base 2019;80:18-22. [PMID: 30733896 DOI: 10.1055/s-0038-1660846] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 259 |
Karin M. New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. Precis Clin Med. 2018;1:21-28. [PMID: 30687560 DOI: 10.1093/pcmedi/pby005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 260 |
Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S, Hanley SJB, Yue J, Watari H, Sakuragi N. Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer. Oncogene 2018;37:5257-68. [PMID: 29855617 DOI: 10.1038/s41388-018-0347-4] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 13.6] [Reference Citation Analysis]
|
| 261 |
Wang Y, Wang H, Yao H, Li C, Fang JY, Xu J. Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion. Front Pharmacol 2018;9:536. [PMID: 29910728 DOI: 10.3389/fphar.2018.00536] [Cited by in Crossref: 129] [Cited by in F6Publishing: 140] [Article Influence: 25.8] [Reference Citation Analysis]
|
| 262 |
Daaboul HE, El-sibai M. Treatment Strategies in Colorectal Cancer. Colorectal Cancer - Diagnosis, Screening and Management 2018. [DOI: 10.5772/intechopen.71620] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 263 |
Wang Y, Liu J, Yang X, Liu Y, Liu Y, Li Y, Sun L, Yang X, Niu H. Bacillus Calmette-Guérin and anti-PD-L1 combination therapy boosts immune response against bladder cancer. Onco Targets Ther 2018;11:2891-9. [PMID: 29844686 DOI: 10.2147/OTT.S165840] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 264 |
Vartuli RL, Zhou H, Zhang L, Powers RK, Klarquist J, Rudra P, Vincent MY, Ghosh D, Costello JC, Kedl RM, Slansky JE, Zhao R, Ford HL. Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. J Clin Invest 2018;128:2535-50. [PMID: 29757193 DOI: 10.1172/JCI96784] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 265 |
Witt DA, Donson AM, Amani V, Moreira DC, Sanford B, Hoffman LM, Handler MH, Levy JMM, Jones KL, Nellan A, Foreman NK, Griesinger AM. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer 2018;65:e26960. [PMID: 29350470 DOI: 10.1002/pbc.26960] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 266 |
Jesinghaus M, Steiger K, Slotta-Huspenina J, Drecoll E, Pfarr N, Meyer P, Konukiewitz B, Bettstetter M, Wieczorek K, Ott K, Feith M, Langer R, Weichert W, Specht K, Boxberg M. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping. Oncotarget 2017;8:46756-68. [PMID: 28657901 DOI: 10.18632/oncotarget.18606] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 267 |
Broos K, Keyaerts M, Lecocq Q, Renmans D, Nguyen T, Escors D, Liston A, Raes G, Breckpot K, Devoogdt N. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget 2017;8:41932-46. [PMID: 28410210 DOI: 10.18632/oncotarget.16708] [Cited by in Crossref: 70] [Cited by in F6Publishing: 75] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 268 |
Wieser V, Gaugg I, Fleischer M, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Zeimet AG, Fiegl H, Marth C. BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer. Oncotarget 2018;9:17501-11. [PMID: 29707124 DOI: 10.18632/oncotarget.24770] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 269 |
Wieser V, Gaugg I, Fleischer M, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Zeimet AG, Fiegl H, Marth C. BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer. Oncotarget 2018;9:17501-11. [PMID: 29707124 DOI: 10.18632/oncotarget.24770] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 270 |
Tretiakova M, Fulton R, Kocherginsky M, Long T, Ussakli C, Antic T, Gown A. Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression. Mod Pathol 2018;31:623-32. [PMID: 29271413 DOI: 10.1038/modpathol.2017.188] [Cited by in Crossref: 84] [Cited by in F6Publishing: 90] [Article Influence: 16.8] [Reference Citation Analysis]
|
| 271 |
Ponomarev V. Advancing Immune and Cell-Based Therapies Through Imaging. Mol Imaging Biol 2017;19:379-84. [PMID: 28271366 DOI: 10.1007/s11307-017-1069-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 272 |
Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther 2018;11:955-65. [PMID: 29503570 DOI: 10.2147/OTT.S153290] [Cited by in Crossref: 165] [Cited by in F6Publishing: 181] [Article Influence: 33.0] [Reference Citation Analysis]
|
| 273 |
Roufas C, Chasiotis D, Makris A, Efstathiades C, Dimopoulos C, Zaravinos A. The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis. Front Oncol 2018;8:27. [PMID: 29515971 DOI: 10.3389/fonc.2018.00027] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 274 |
Ren X, Wu H, Lu J, Zhang Y, Luo Y, Xu Q, Shen S, Liang Z. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer. Cancer Biol Ther 2018;19:373-80. [PMID: 29336717 DOI: 10.1080/15384047.2018.1423919] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 275 |
Machado I, López-Guerrero JA, Scotlandi K, Picci P, Llombart-Bosch A. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT). Virchows Arch 2018;472:815-24. [PMID: 29445891 DOI: 10.1007/s00428-018-2316-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 276 |
Rom-Jurek EM, Kirchhammer N, Ugocsai P, Ortmann O, Wege AK, Brockhoff G. Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice. Int J Mol Sci 2018;19:E563. [PMID: 29438316 DOI: 10.3390/ijms19020563] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 277 |
Ueda T, Aokage K, Nishikawa H, Neri S, Nakamura H, Sugano M, Tane K, Miyoshi T, Kojima M, Fujii S, Kuwata T, Ochiai A, Kusumoto M, Suzuki K, Tsuboi M, Ishii G. Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung. J Cancer Res Clin Oncol 2018;144:835-44. [PMID: 29435735 DOI: 10.1007/s00432-018-2602-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 278 |
Albitar M, Sudarsanam S, Ma W, Jiang S, Chen W, Funari V, Blocker F, Agersborg S. Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer. Oncotarget 2018;9:13682-93. [PMID: 29568386 DOI: 10.18632/oncotarget.24455] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 279 |
Catalano C, da Silva Filho MI, Frank C, Jiraskova K, Vymetalkova V, Levy M, Liska V, Vycital O, Naccarati A, Vodickova L, Hemminki K, Vodicka P, Weber ANR, Försti A. Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer. PLoS One 2018;13:e0192385. [PMID: 29408916 DOI: 10.1371/journal.pone.0192385] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 280 |
Kawachi A, Yoshida H, Kitano S, Ino Y, Kato T, Hiraoka N. Tumor-associated CD204+ M2 macrophages are unfavorable prognostic indicators in uterine cervical adenocarcinoma. Cancer Sci 2018;109:863-70. [PMID: 29274107 DOI: 10.1111/cas.13476] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 281 |
Dillinger B, Ahmadi-Erber S, Lau M, Hoelzl MA, Erhart F, Juergens B, Fuchs D, Heitger A, Ladisch S, Dohnal AM. IFN-γ and tumor gangliosides: Implications for the tumor microenvironment. Cell Immunol 2018;325:33-40. [PMID: 29402391 DOI: 10.1016/j.cellimm.2018.01.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 282 |
Yoon DH, Osborn MJ, Tolar J, Kim CJ. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T. Int J Mol Sci 2018;19:E340. [PMID: 29364163 DOI: 10.3390/ijms19020340] [Cited by in Crossref: 110] [Cited by in F6Publishing: 113] [Article Influence: 22.0] [Reference Citation Analysis]
|
| 283 |
Carretero-González A, Lora D, Ghanem I, Zugazagoitia J, Castellano D, Sepúlveda JM, López-Martin JA, Paz-Ares L, de Velasco G. Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. Oncotarget 2018;9:8706-15. [PMID: 29492229 DOI: 10.18632/oncotarget.24283] [Cited by in Crossref: 53] [Cited by in F6Publishing: 64] [Article Influence: 10.6] [Reference Citation Analysis]
|
| 284 |
Bellone S, Buza N, Choi J, Zammataro L, Gay L, Elvin J, Rimm DL, Liu Y, Ratner ES, Schwartz PE, Santin AD. Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 2018;24:3282-91. [PMID: 29351920 DOI: 10.1158/1078-0432.CCR-17-1805] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 285 |
Liu J, Zhang C, Hu J, Tian Q, Wang X, Gu H, Zhang S, Zhao D, Fan R. Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis. Oncotarget 2018;9:12400-7. [PMID: 29552320 DOI: 10.18632/oncotarget.24249] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 286 |
Yoshida S, Nagatsuka H, Nakano K, Kogashiwa Y, Ebihara Y, Yano M, Yasuda M. Significance of PD-L1 Expression in Tongue Cancer Development. Int J Med Sci 2018;15:1723-30. [PMID: 30588196 DOI: 10.7150/ijms.27860] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 287 |
Jain A, Shannon VR, Sheshadri A. Immune-Related Adverse Events: Pneumonitis. Adv Exp Med Biol 2018;995:131-49. [PMID: 30539509 DOI: 10.1007/978-3-030-02505-2_6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 288 |
Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients. Clin Cancer Res 2018;24:896-905. [PMID: 29233903 DOI: 10.1158/1078-0432.CCR-17-2664] [Cited by in Crossref: 310] [Cited by in F6Publishing: 323] [Article Influence: 51.7] [Reference Citation Analysis]
|
| 289 |
Boxberg M, Steiger K, Lenze U, Rechl H, von Eisenhart-Rothe R, Wörtler K, Weichert W, Langer R, Specht K. PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy. Oncoimmunology 2018;7:e1389366. [PMID: 29399389 DOI: 10.1080/2162402X.2017.1389366] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 290 |
Lee KS, Lee K, Yun S, Moon S, Park Y, Han JH, Kim CY, Lee HS, Choe G. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma. J Neurooncol 2018;136:453-61. [PMID: 29147863 DOI: 10.1007/s11060-017-2675-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 291 |
Seo AN, Kang BW, Kwon OK, Park KB, Lee SS, Chung HY, Yu W, Bae HI, Jeon SW, Kang H, Kim JG. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. Br J Cancer 2017;117:1753-60. [PMID: 29073638 DOI: 10.1038/bjc.2017.369] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 292 |
Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M, Emens LA, Hrinczenko B, Edenfield W, Gurtler J, von Heydebreck A, Grote HJ, Chin K, Hamilton EP. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018;167:671-686. [PMID: 29063313 DOI: 10.1007/s10549-017-4537-5] [Cited by in Crossref: 366] [Cited by in F6Publishing: 400] [Article Influence: 61.0] [Reference Citation Analysis]
|
| 293 |
Chen Y, Xue SA, Behboudi S, Mohammad GH, Pereira SP, Morris EC. Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients. Clin Cancer Res 2017;23:6178-89. [PMID: 28710313 DOI: 10.1158/1078-0432.CCR-17-1185] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 294 |
Mizutani K, Horie K, Nagai S, Tsuchiya T, Saigo C, Kobayashi K, Miyazaki T, Deguchi T. Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report. Mol Clin Oncol 2017;7:988-90. [PMID: 29285361 DOI: 10.3892/mco.2017.1449] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 295 |
Memarnejadian A, Meilleur CE, Shaler CR, Khazaie K, Bennink JR, Schell TD, Haeryfar SMM. PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+ T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination. J Immunol 2017;199:3348-59. [PMID: 28939757 DOI: 10.4049/jimmunol.1700643] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 296 |
Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep 2017;7:10541. [PMID: 28874817 DOI: 10.1038/s41598-017-10940-8] [Cited by in Crossref: 199] [Cited by in F6Publishing: 212] [Article Influence: 33.2] [Reference Citation Analysis]
|
| 297 |
Cavalcanti E, Armentano R, Valentini AM, Chieppa M, Caruso ML. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death Dis. 2017;8:e3004. [PMID: 28837143 DOI: 10.1038/cddis.2017.401] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 298 |
Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J. Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2018;20:274-85. [PMID: 28815456 DOI: 10.1007/s12094-017-1719-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 299 |
Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, Lopci E. Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. Eur J Nucl Med Mol Imaging 2017;44:2310-25. [PMID: 28815334 DOI: 10.1007/s00259-017-3802-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 300 |
Skalniak L, Zak KM, Guzik K, Magiera K, Musielak B, Pachota M, Szelazek B, Kocik J, Grudnik P, Tomala M, Krzanik S, Pyrc K, Dömling A, Dubin G, Holak TA. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget 2017;8:72167-81. [PMID: 29069777 DOI: 10.18632/oncotarget.20050] [Cited by in Crossref: 150] [Cited by in F6Publishing: 155] [Article Influence: 25.0] [Reference Citation Analysis]
|
| 301 |
Ahn H, Yang JM, Kim H, Chung JH, Ahn SH, Jeong WJ, Paik JH. Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma. Oncotarget 2017;8:66178-94. [PMID: 29029502 DOI: 10.18632/oncotarget.19842] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 302 |
Pichler R, Heidegger I, Fritz J, Danzl M, Sprung S, Zelger B, Brunner A, Pircher A. PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. Oncotarget 2017;8:66849-64. [PMID: 28978000 DOI: 10.18632/oncotarget.19913] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 303 |
van Erp AEM, Versleijen-Jonkers YMH, Hillebrandt-Roeffen MHS, van Houdt L, Gorris MAJ, van Dam LS, Mentzel T, Weidema ME, Savci-Heijink CD, Desar IME, Merks HHM, van Noesel MM, Shipley J, van der Graaf WTA, Flucke UE, Meyer-Wentrup FAG. Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. Oncotarget 2017;8:71371-84. [PMID: 29050367 DOI: 10.18632/oncotarget.19071] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 304 |
Siebert N, Zumpe M, Jüttner M, Troschke-Meurer S, Lode HN. PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO. Oncoimmunology 2017;6:e1343775. [PMID: 29123953 DOI: 10.1080/2162402X.2017.1343775] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 305 |
Šmahel M. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. Int J Mol Sci 2017;18:E1331. [PMID: 28635644 DOI: 10.3390/ijms18061331] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 306 |
Li J, Baird MA, Davis MA, Tai W, Zweifel LS, Adams Waldorf KM, Gale M Jr, Rajagopal L, Pierce RH, Gao X. Dramatic enhancement of the detection limits of bioassays via ultrafast deposition of polydopamine. Nat Biomed Eng 2017;1:0082. [PMID: 29082104 DOI: 10.1038/s41551-017-0082] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 307 |
Shao Y, Zhu W, Da J, Xu M, Wang Y, Zhou J, Wang Z. Bisdemethoxycurcumin in combination with α-PD-L1 antibody boosts immune response against bladder cancer. Onco Targets Ther 2017;10:2675-83. [PMID: 28579805 DOI: 10.2147/OTT.S130653] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 308 |
Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, Zanconati F, Generali D. Advances in systemic therapy for metastatic breast cancer: future perspectives. Med Oncol. 2017;34:119. [PMID: 28526922 DOI: 10.1007/s12032-017-0975-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 309 |
Chang K, Qu Y, Dai B, Zhao JY, Gan H, Shi G, Zhu Y, Shen Y, Zhu Y, Zhang H, Ye D. PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness. Sci Rep 2017;7:2074. [PMID: 28522811 DOI: 10.1038/s41598-017-02005-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 310 |
Wangpaichitr M, Kandemir H, Li YY, Wu C, Nguyen D, Feun LG, Kuo MT, Savaraj N. Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer. Cell Dev Biol 2017;6:183. [PMID: 28819582 DOI: 10.4172/2168-9296.1000183] [Cited by in Crossref: 14] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 311 |
Linedale R, Schmidt C, King BT, Ganko AG, Simpson F, Panizza BJ, Leggatt GR. Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients. PLoS One 2017;12:e0175755. [PMID: 28423034 DOI: 10.1371/journal.pone.0175755] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 312 |
Burmeister K, Quagliata L, Andreozzi M, Eppenberger-Castori S, Matter MS, Perrina V, Grobholz R, Jochum W, Horber D, Moosmann P, Lehmann F, Köberle D, Ng CK, Piscuoglio S, Tornillo L, Terracciano LM. Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. PLoS One 2017;12:e0175563. [PMID: 28403223 DOI: 10.1371/journal.pone.0175563] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 313 |
Aust S, Felix S, Auer K, Bachmayr-Heyda A, Kenner L, Dekan S, Meier SM, Gerner C, Grimm C, Pils D. Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer. Sci Rep 2017;7:42929. [PMID: 28266500 DOI: 10.1038/srep42929] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 314 |
Kluger HM, Zito CR, Turcu G, Baine MK, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clin Cancer Res 2017;23:4270-9. [PMID: 28223273 DOI: 10.1158/1078-0432.CCR-16-3146] [Cited by in Crossref: 87] [Cited by in F6Publishing: 92] [Article Influence: 14.5] [Reference Citation Analysis]
|
| 315 |
Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, Cheng X. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy. J Ovarian Res 2017;10:9. [PMID: 28187748 DOI: 10.1186/s13048-017-0304-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 316 |
Qu HX, Zhao LP, Zhan SH, Geng CX, Xu L, Xin YN, Jiang XJ. Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis. J Thorac Dis 2016;8:3197-204. [PMID: 28066599 DOI: 10.21037/jtd.2016.11.01] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 317 |
Sadighi S, Sharifian R, Kazemimanesh M, Muhammadnejad A, Shahosseini Z, Amanpour S, Muhammadnejad S. Down-regulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in a murine breast cancer model. Iran J Basic Med Sci 2021;24:537-44. [PMID: 34094037 DOI: 10.22038/ijbms.2021.54383.12221] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
